Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8+ T cells

Claudia Wrzesinski, Chrystal M. Paulos, Luca Gattinoni, Douglas C. Palmer, Andrew Kaiser, Zhiya Yu, Steven A. Rosenberg, Nicholas P. Restifo

Research output: Contribution to journalArticle

Abstract

Depleting host immune elements with nonmyeloablative regimens prior to the adoptive transfer of tumor-specific CD8+ T cells significantly enhances tumor treatment. In the current study, superior antitumor efficacy was achieved by further increasing the intensity of lymphodepletion to a level that required HSC transplantation. Surprisingly, the HSC transplant and not the increased lymphodepletion caused a robust expansion of adoptively transferred tumor-specific CD8+ T cells. The HSC-driven cell expansion of effector, but not of naive, CD8+ T cells was independent of in vivo restimulation by MHC class I-expressing APCs. Simultaneously, HSCs also facilitated the reconstitution of the host lymphoid compartment, including inhibitory elements, not merely via the production of progeny cells but by enhancing the expansion of cells that had survived lymphodepletion. Profound lymphodepletion, by myeloablation or by genetic means, focused the nonspecific HSC boost preferentially toward the transferred tumor-specific T cells, leading to successful tumor treatment. These findings indicate that CD8+ T cell-mediated tumor responses can be efficiently driven by HSCs in the myeloablative setting and have substantial implications for the design of new antitumor immunotherapies.

Original languageEnglish (US)
Pages (from-to)492-501
Number of pages10
JournalJournal of Clinical Investigation
Volume117
Issue number2
DOIs
StatePublished - Feb 1 2007
Externally publishedYes

Fingerprint

Hematopoietic Stem Cells
T-Lymphocytes
Neoplasms
Adoptive Transfer
Immunotherapy
Transplantation
Transplants
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Wrzesinski, C., Paulos, C. M., Gattinoni, L., Palmer, D. C., Kaiser, A., Yu, Z., ... Restifo, N. P. (2007). Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8+ T cells. Journal of Clinical Investigation, 117(2), 492-501. https://doi.org/10.1172/JCI30414

Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8+ T cells. / Wrzesinski, Claudia; Paulos, Chrystal M.; Gattinoni, Luca; Palmer, Douglas C.; Kaiser, Andrew; Yu, Zhiya; Rosenberg, Steven A.; Restifo, Nicholas P.

In: Journal of Clinical Investigation, Vol. 117, No. 2, 01.02.2007, p. 492-501.

Research output: Contribution to journalArticle

Wrzesinski, C, Paulos, CM, Gattinoni, L, Palmer, DC, Kaiser, A, Yu, Z, Rosenberg, SA & Restifo, NP 2007, 'Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8+ T cells', Journal of Clinical Investigation, vol. 117, no. 2, pp. 492-501. https://doi.org/10.1172/JCI30414
Wrzesinski, Claudia ; Paulos, Chrystal M. ; Gattinoni, Luca ; Palmer, Douglas C. ; Kaiser, Andrew ; Yu, Zhiya ; Rosenberg, Steven A. ; Restifo, Nicholas P. / Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8+ T cells. In: Journal of Clinical Investigation. 2007 ; Vol. 117, No. 2. pp. 492-501.
@article{8a8b89061f4b46f488e12c65b0a5a3d7,
title = "Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8+ T cells",
abstract = "Depleting host immune elements with nonmyeloablative regimens prior to the adoptive transfer of tumor-specific CD8+ T cells significantly enhances tumor treatment. In the current study, superior antitumor efficacy was achieved by further increasing the intensity of lymphodepletion to a level that required HSC transplantation. Surprisingly, the HSC transplant and not the increased lymphodepletion caused a robust expansion of adoptively transferred tumor-specific CD8+ T cells. The HSC-driven cell expansion of effector, but not of naive, CD8+ T cells was independent of in vivo restimulation by MHC class I-expressing APCs. Simultaneously, HSCs also facilitated the reconstitution of the host lymphoid compartment, including inhibitory elements, not merely via the production of progeny cells but by enhancing the expansion of cells that had survived lymphodepletion. Profound lymphodepletion, by myeloablation or by genetic means, focused the nonspecific HSC boost preferentially toward the transferred tumor-specific T cells, leading to successful tumor treatment. These findings indicate that CD8+ T cell-mediated tumor responses can be efficiently driven by HSCs in the myeloablative setting and have substantial implications for the design of new antitumor immunotherapies.",
author = "Claudia Wrzesinski and Paulos, {Chrystal M.} and Luca Gattinoni and Palmer, {Douglas C.} and Andrew Kaiser and Zhiya Yu and Rosenberg, {Steven A.} and Restifo, {Nicholas P.}",
year = "2007",
month = "2",
day = "1",
doi = "10.1172/JCI30414",
language = "English (US)",
volume = "117",
pages = "492--501",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "2",

}

TY - JOUR

T1 - Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8+ T cells

AU - Wrzesinski, Claudia

AU - Paulos, Chrystal M.

AU - Gattinoni, Luca

AU - Palmer, Douglas C.

AU - Kaiser, Andrew

AU - Yu, Zhiya

AU - Rosenberg, Steven A.

AU - Restifo, Nicholas P.

PY - 2007/2/1

Y1 - 2007/2/1

N2 - Depleting host immune elements with nonmyeloablative regimens prior to the adoptive transfer of tumor-specific CD8+ T cells significantly enhances tumor treatment. In the current study, superior antitumor efficacy was achieved by further increasing the intensity of lymphodepletion to a level that required HSC transplantation. Surprisingly, the HSC transplant and not the increased lymphodepletion caused a robust expansion of adoptively transferred tumor-specific CD8+ T cells. The HSC-driven cell expansion of effector, but not of naive, CD8+ T cells was independent of in vivo restimulation by MHC class I-expressing APCs. Simultaneously, HSCs also facilitated the reconstitution of the host lymphoid compartment, including inhibitory elements, not merely via the production of progeny cells but by enhancing the expansion of cells that had survived lymphodepletion. Profound lymphodepletion, by myeloablation or by genetic means, focused the nonspecific HSC boost preferentially toward the transferred tumor-specific T cells, leading to successful tumor treatment. These findings indicate that CD8+ T cell-mediated tumor responses can be efficiently driven by HSCs in the myeloablative setting and have substantial implications for the design of new antitumor immunotherapies.

AB - Depleting host immune elements with nonmyeloablative regimens prior to the adoptive transfer of tumor-specific CD8+ T cells significantly enhances tumor treatment. In the current study, superior antitumor efficacy was achieved by further increasing the intensity of lymphodepletion to a level that required HSC transplantation. Surprisingly, the HSC transplant and not the increased lymphodepletion caused a robust expansion of adoptively transferred tumor-specific CD8+ T cells. The HSC-driven cell expansion of effector, but not of naive, CD8+ T cells was independent of in vivo restimulation by MHC class I-expressing APCs. Simultaneously, HSCs also facilitated the reconstitution of the host lymphoid compartment, including inhibitory elements, not merely via the production of progeny cells but by enhancing the expansion of cells that had survived lymphodepletion. Profound lymphodepletion, by myeloablation or by genetic means, focused the nonspecific HSC boost preferentially toward the transferred tumor-specific T cells, leading to successful tumor treatment. These findings indicate that CD8+ T cell-mediated tumor responses can be efficiently driven by HSCs in the myeloablative setting and have substantial implications for the design of new antitumor immunotherapies.

UR - http://www.scopus.com/inward/record.url?scp=33846787125&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846787125&partnerID=8YFLogxK

U2 - 10.1172/JCI30414

DO - 10.1172/JCI30414

M3 - Article

C2 - 17273561

AN - SCOPUS:33846787125

VL - 117

SP - 492

EP - 501

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 2

ER -